Form 4: Adverum Biotechnologies Director Reed Tuckson Granted Stock Options

Director Reed Tuckson of Adverum Biotechnologies was granted stock options exercisable at $7.32, vesting on June 17, 2025, or the 2025 annual meeting, as reported in a Form 4 filing.

Summary

• Reed Tuckson, a director of Adverum Biotechnologies, Inc., was granted stock options on June 17, 2024.
• The options allow him to purchase 10,520 shares of Adverum's common stock at an exercise price of $7.32 per share.
• The options vest on the earlier of June 17, 2025, or the date of the 2025 annual meeting of stockholders, contingent upon continued service with the company.
• Vesting is accelerated upon a change of control.
• A Power of Attorney was executed on March 17, 2024, granting certain officers of Adverum Biotechnologies the authority to execute and file Forms 3, 4, and 5 on behalf of Reed Tuckson.

Sentiment

Score: 7

Explanation: The document reflects a standard compensation practice (stock options) for a director, indicating a positive alignment of interests with shareholders. There are no overtly negative aspects presented.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• Accelerated vesting upon a change of control could incentivize the director to support value-enhancing transactions.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting of stock options is tied to continued service, suggesting an expectation of ongoing contributions from the director.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel, aligning their interests with the long-term success of the company. This is a standard compensation practice.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options to incentivize their directors and officers.
• The vesting schedule and exercise price are generally aligned with industry norms, although specific terms can vary based on company performance and individual contributions.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the director to contribute to the company's success.
• The director benefits from the potential to profit from an increase in the company's stock price.

Key Dates